← Back to results
NCT06023446ENROLLING_BY_INVITATION

Can (Optical Coherence Tomography) Pictures of the Retina Detect Alzheimer's Disease at Its Earliest Stages?

Illuminating Glial Dysfunction in Alzheimer's Disease With Optical Coherence Tomography

Sponsor: University of California, Davis + National Institute on Aging (NIA)

No open prediction endpoints

Endpoints are classified and published by ProgramSignal analysts.

Request endpoint coverage

Key Facts

Study type
OBSERVATIONAL
Conditions
Alzheimer Disease, Mild Cognitive Impairment
Interventions
Optical Coherence Tomography
Enrollment
100 participants
Primary completion
Feb 2028
Study completion
Feb 2028
First posted
Sep 2023
Last updated
Dec 2025

Primary Endpoints (CT.gov)

Light-dependent Change in Optical Coherence Tomography Images

Time frame: Day 1 (less than two hours)

Eligibility Criteria

Inclusion Criteria: * By clinician (or prior research) assessment, known to either be cognitively normal, or have mild cognitive impairment * Known Alzheimer's biomarker status. As of 2023-JUL, this must either be an amyloid PET scan, or cerebrospinal fluid measurement of amyloid and tau levels. * NOTE: Although this is a study of the eyes, age-typical ocular/vision complaints are permissible, so long as the the retina is thought to be healthy. This list of acceptable conditions includes most people who: * wear glasses * wear contacts * use over-the-counter eye drops * have mild cataracts (no surgery scheduled) * had cataracts removed * had eye muscle surgery (e.g., to correct eye misalignment) * had eyelid surgery (blepharoplasty) * are monitored by an ophthalmologist in case a problem with the retina develops (this is sometimes suggested for people with diabetes), but one or both retinas is/are thought to be completely healthy Exclusion Criteria: * Pregnant women

Read full criteria on CT.gov →

✦ Analyst Commentary

Expert commentary on why this trial matters and what to watch for.

Request coverage →

Source

Open on ClinicalTrials.gov